'Half dose' presentation slideshows

Pathophysiology of Combination Therapy in AMI

Pathophysiology of Combination Therapy in AMI. Combination Therapy. Reduces Reinfarction*. ? Thrombus. ? % Stenosis ? Minimum Diameter. ? Myocardial Blush ? ST Resolution. ? Epicardial Flow. Facilitates PCI. ? Myocardial Flow. *Gibson et al. J Am Coll Cardiol. 1995;25:582-589.

533 views • 39 slides

Pathophysiology of Combination Therapy in AMI

Pathophysiology of Combination Therapy in AMI. Combination Therapy. Reduces Reinfarction*. ? Thrombus. ? % Stenosis ? Minimum Diameter. ? Myocardial Blush ? ST Resolution. ? Epicardial Flow. Facilitates PCI. ? Myocardial Flow. *Gibson et al. J Am Coll Cardiol. 1995;25:582-589.

395 views • 39 slides

Hemostatic Agents: Cost-Effectiveness Issues

Hemostatic Agents: Cost-Effectiveness Issues. Peter K. Smith, MD Professor and Chief Thoracic Surgery Duke University. Tranexamic RCT Cardiac Surgery (n=163) 10 mg/kg (incision) ? 1 mg/kg/hr. Horrow et al. Circulation 1991; 84:2063. Aprotinin vs EACA Efficacy - Demographics.

453 views • 34 slides

Levamlodipine Besylate New CCB half dose, save efficiency and safety

520 views • 22 slides

Results

FINESSE.

106 views • 1 slides